A Agilent Technologies Inc.

Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence

. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, and the (UC San Diego), one of the top-ranked public research universities in the world, today announced an innovative scientific collaboration to establish the .

The Agilent CoE, located at UC San Diego’s School of Medicine, will foster collaboration and innovation among researchers from Agilent and UC San Diego, and other institutions and industry partners. The CoE will serve as a hub for academic and pharma/biopharma researchers in the region, enabling access to vital analytical instrumentation and providing education, training, and application development opportunities.

"This important initiative will improve our understanding of disease mechanisms at the cellular level—and drive the development of better methods for editing and engineering cells to treat diseases, enhance immunity, and create novel bioproducts,” said Mike McMullen, Agilent President and CEO.

The CoE will leverage Agilent instrumentation, including cell analysis and mass spectroscopy solutions, to support an ambitious transdisciplinary initiative: Decode Eukaryotic Cellular Intelligence, a research program that aims to understand how eukaryotic cells sense, decide, and act in complex and uncertain environments, with implications for health and disease.

“We are thrilled to partner with Agilent to launch the Agilent CoE in Cellular Intelligence at UC San Diego, which will advance our understanding of the fundamental principles of life and the origin of biological complexity,” added Dr. Pradipta Ghosh, Professor of Medicine and Cellular and Molecular Medicine at UC San Diego and Founding Director of the program.

The program is based on the that eukaryotic cells function as deep reinforcement learning (RL) agents that use interlinked switch circuits of biological intelligence to adapt and survive. It combines experimental, computational, and theoretical approaches to decode the molecular and cellular mechanisms of these switch circuits and explore their implications for health and disease.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the . Follow Agilent on and .

About UC San Diego

At the , a culture of risk-taking, collaboration and innovation emerged early on. Established in 1960, UC San Diego has been shaped by exceptional scholars who aren’t afraid to push boundaries, challenge expectations and redefine conventional wisdom in order to make our world better. The only criterion our founders had for their campus was that it must be distinctive – and being experimental has been the norm since day one. UC San Diego is a top-ranked public research institution and one of the most applied to universities in the nation. Learn more at .

EN
02/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch